Aberrant formation of the neutrophil extracellular trap and the expression of the PLEKHA1 in systemic lupus erythematosus and ulcerative colitis
- PMID: 40379887
- DOI: 10.1007/s11010-025-05300-4
Aberrant formation of the neutrophil extracellular trap and the expression of the PLEKHA1 in systemic lupus erythematosus and ulcerative colitis
Abstract
Systemic lupus erythematosus (SLE) and ulcerative colitis (UC) are both chronic autoimmune diseases with unclear shared mechanisms, largely due to limited mechanistic studies and clinical research cohorts. Transcriptome datasets from the Gene Expression Omnibus (GEO) database were analyzed for SLE and UC, identifying differentially expressed genes (DEGs). Weighted gene co-expression network analysis (WGCNA) identified significant module genes, including PLEKHA1. The diagnostic potential of PLEKHA1 was confirmed using machine-learning algorithms and real-time fluorescence quantitative PCR (RT-PCR) in clinical samples. Additionally, the study explored the link between PLEKHA1 and neutrophil extracellular trap (NET) formation. Our analyses identified transcriptional signatures associated with neutrophil degranulation and NET formation pathways in the peripheral blood of both SLE and UC, a perspective not previously explored. PLEKHA1 was identified as a promising biomarker that may impact NET formation. Pathway enrichment analyses indicated that PLEKHA1 plays a regulatory role in NET formation in both diseases. This study provides novel transcriptional evidence by proposing neutrophil degranulation and NET formation as common pathways in SLE and UC, with PLEKHA1 acting as a shared diagnostic gene. PLEKHA1 may regulate neutrophil activation and immune response, influencing NET formation and neutrophil degranulation in SLE patients' peripheral blood.
Keywords: Biomarker; Lasso regression; Machine learning; Neutrophil extracellular trap; Systemic lupus erythematosus; Ulcerative colitis.
© 2025. The Author(s), under exclusive licence to Springer Science+Business Media, LLC, part of Springer Nature.
Conflict of interest statement
Declarations. Competing interests: The authors declare that they have no competing interests. Ethical approval: The studies involving the collection of blood samples were conducted with full ethical approval from the Ethics Committee of the Third Xiangya Hospital (Approval Number: 23675). Consent to participate: Not applicable. Consent to participate: Not applicable.
References
-
- Lazar S, Kahlenberg JM (2023) Systemic lupus erythematosus: new diagnostic and therapeutic approaches. Annu Rev Med 74:339–352. https://doi.org/10.1146/annurev-med-043021-032611 - DOI - PubMed
-
- Li H, Boulougoura A, Endo Y, Tsokos GC (2022) Abnormalities of T cells in systemic lupus erythematosus: new insights in pathogenesis and therapeutic strategies. J Autoimmun 132:102870. https://doi.org/10.1016/j.jaut.2022.102870 - DOI - PubMed
-
- Fasano S, Milone A, Nicoletti GF, Isenberg DA, Ciccia F (2023) Precision medicine in systemic lupus erythematosus. Nat Rev Rheumatol 19:331–342. https://doi.org/10.1038/s41584-023-00948-y - DOI - PubMed
-
- Frittoli RB, Vivaldo JF, Costallat LTL, Appenzeller S (2021) Gastrointestinal involvement in systemic lupus erythematosus: a systematic review. J Transl Autoimmun 4:100106. https://doi.org/10.1016/j.jtauto.2021.100106 - DOI - PubMed - PMC
-
- Alves SC, Fasano S, Isenberg DA (2016) Autoimmune gastrointestinal complications in patients with systemic lupus erythematosus: case series and literature review. Lupus 25:1509–1519. https://doi.org/10.1177/0961203316655210 - DOI - PubMed
LinkOut - more resources
Full Text Sources